Iambic Therapeutics

Iambic Therapeutics is a clinical-stage, AI-native drug-discovery company based in San Diego, California. Founded in 2019, the company focuses on developing novel medicines for oncology and neurological diseases using its proprietary AI-driven platform. Iambic combines expertise in artificial intelligence with drug discovery to create a pipeline of potential first-in-class and best-in-class clinical assets. The company operates through two main revenue streams. Its proprietary pipeline includes small-molecule oncology drugs, with its lead asset, IAM1363, currently in clinical trials. Additionally, Iambic offers a platform-as-a-service model, partnering with major pharmaceutical companies like Takeda, Bayer, and Eli Lilly to license its AI platform for drug discovery. The platform features advanced AI models, including Enchant, NeuralPLEXER, Magnet, and OrbNet, which enhance the drug development process.

Iambic Therapeutics is a clinical-stage, AI-native drug-discovery company based in San Diego, California. Founded in 2019, the company focuses on developing novel medicines for oncology and neurological diseases… Valuation shown is a Lounge estimate at 10x ARR (no reported valuation).